The slip
PARKINSON RECEIPTno. 15740
31 Oct 2026, 02:25 UTCdopamine neurons, braak
predictionCEP131 in dopamine neurons tracks Braak Lewy-body stage
registerede4ae3b03702bbf9c
discovery-0.15 p=0.702 n=9
replication-0.08 p=0.840 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.15, p 0.702)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTe92df7dbc32ebdd9e3f5c093…
follows 5d516f69a56b…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 15740: CEP131 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.754, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.735, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.774, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.04, sign flips 4; without severely affected donors -0.08 (p 0.754, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.69 (p 0.0016, n 18) vs -0.08 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CEP131 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CEP131 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.82 p 0.0034 (needs p < 1.5e-4)